WO1993018764A3 - Verapamil hcl formulation and other ophthalmic solutions with buffer system for ocular administration - Google Patents
Verapamil hcl formulation and other ophthalmic solutions with buffer system for ocular administration Download PDFInfo
- Publication number
- WO1993018764A3 WO1993018764A3 PCT/US1993/002549 US9302549W WO9318764A3 WO 1993018764 A3 WO1993018764 A3 WO 1993018764A3 US 9302549 W US9302549 W US 9302549W WO 9318764 A3 WO9318764 A3 WO 9318764A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- verapamil hcl
- buffer system
- ocular administration
- ophthalmic solutions
- hcl formulation
- Prior art date
Links
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002997 ophthalmic solution Substances 0.000 title abstract 2
- 229960001722 verapamil Drugs 0.000 title abstract 2
- 239000007853 buffer solution Substances 0.000 title 1
- 239000000872 buffer Substances 0.000 abstract 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract 1
- 239000004327 boric acid Substances 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229940054534 ophthalmic solution Drugs 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
An aqueous ophthalmic solution is disclosed in which one or more acive ingredients in ionized form are gradually brought to undissociated, free base form by lacrimal solution acting against the affect of a plurality of buffers. The affect of each buffer is overcome sequentially by the lacrimal fluid. A preferred formulation includes verapamil HCl as the active ingredient in ionized form and includes as buffers: boric acid at 2.8 %, disodium edetate at 0.18 %, dextrose at 0.3 %, and polyvinylpyrrolidone at 2.0 %.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5516746A JPH06511014A (en) | 1992-03-18 | 1993-03-18 | Ophthalmic solutions, such as verapamil hydrochloride formulations containing a buffer system, for administration to the eye |
| CZ932600A CZ260093A3 (en) | 1992-03-18 | 1993-03-18 | VERAPAMIL HCl PREPARATION AND OTHER OPHTHALMIC SOLUTIONS WITH A BUFFER SYSTEM FOR EYE ADMINISTRATION |
| SK1438-93A SK143893A3 (en) | 1992-03-18 | 1993-03-18 | Verapamil hci formulation and other opthalmic solutions with buffer system for ocular administration |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85324692A | 1992-03-18 | 1992-03-18 | |
| US07/853,246 | 1992-03-18 | ||
| US99199592A | 1992-12-17 | 1992-12-17 | |
| US07/991,995 | 1992-12-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1993018764A2 WO1993018764A2 (en) | 1993-09-30 |
| WO1993018764A3 true WO1993018764A3 (en) | 1993-11-25 |
Family
ID=27127128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1993/002549 WO1993018764A2 (en) | 1992-03-18 | 1993-03-18 | VERAPAMIL HCl FORMULATION AND OTHER OPHTHALMIC SOLUTIONS WITH BUFFER SYSTEM FOR OCULAR ADMINISTRATION |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0589020A4 (en) |
| AU (1) | AU3926093A (en) |
| CA (1) | CA2102110A1 (en) |
| CZ (1) | CZ260093A3 (en) |
| HU (1) | HUT67631A (en) |
| SK (1) | SK143893A3 (en) |
| WO (1) | WO1993018764A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001264261A1 (en) * | 2000-06-19 | 2002-01-02 | Santen Pharmaceutical Co. Ltd. | Aseptics |
| US7022740B2 (en) | 2004-04-29 | 2006-04-04 | Leonard Mackles | Lubricious ophthalmic solutions |
| CN118892446A (en) * | 2023-04-27 | 2024-11-05 | 维眸生物科技(浙江)有限公司 | An ophthalmic composition containing VVN001 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4981871A (en) * | 1987-05-15 | 1991-01-01 | Abelson Mark B | Treatment of ocular hypertension with class I calcium channel blocking agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4470965A (en) * | 1982-10-27 | 1984-09-11 | Usv Pharmaceutical Corporation | Celiprolol for the treatment of glaucoma |
| TW200402B (en) * | 1990-08-13 | 1993-02-21 | Senju Pharma Co |
-
1993
- 1993-03-18 CA CA 2102110 patent/CA2102110A1/en not_active Abandoned
- 1993-03-18 HU HU9303263A patent/HUT67631A/en unknown
- 1993-03-18 WO PCT/US1993/002549 patent/WO1993018764A2/en not_active Application Discontinuation
- 1993-03-18 AU AU39260/93A patent/AU3926093A/en not_active Abandoned
- 1993-03-18 CZ CZ932600A patent/CZ260093A3/en unknown
- 1993-03-18 SK SK1438-93A patent/SK143893A3/en unknown
- 1993-03-18 EP EP19930908438 patent/EP0589020A4/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4981871A (en) * | 1987-05-15 | 1991-01-01 | Abelson Mark B | Treatment of ocular hypertension with class I calcium channel blocking agents |
Non-Patent Citations (2)
| Title |
|---|
| Physician's Desk Reference for Ophthamology, 16 Edition, 1988, pp. 14, 68, 88 and 90. * |
| See also references of EP0589020A4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CZ260093A3 (en) | 1994-07-13 |
| EP0589020A1 (en) | 1994-03-30 |
| HUT67631A (en) | 1995-04-28 |
| EP0589020A4 (en) | 1994-07-06 |
| AU3926093A (en) | 1993-10-21 |
| CA2102110A1 (en) | 1993-09-19 |
| WO1993018764A2 (en) | 1993-09-30 |
| SK143893A3 (en) | 1994-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6479556B2 (en) | Ophthalmic compositions for soft contact lens, method of enhancing wettability of soft contact lens and method of inhibiting terpenoid adsorption | |
| CA2101189A1 (en) | Agglomerated hydrophilic complexes with multi-phasic release characteristics | |
| CA2013188A1 (en) | Preservative system for ophthalmic formulations | |
| KR890004691A (en) | Antiseptic system for ophthalmic preparations | |
| ES2088385T3 (en) | LIPOSOME FORMULATIONS WITH A HIGH ANTINEOPLASTIC AGENT / LIPID AGENT. | |
| CA2004598A1 (en) | Medicinal aerosol formulations | |
| GB2264640B (en) | Microcrystalline cellulose spheroids comprising hydromorphone and a sugar | |
| MXPA03011947A (en) | Olopatadine formulations for topical administration. | |
| ATE58292T1 (en) | MEDICATION CONTAINING L-DOPA. | |
| BR9401199A (en) | Drug preparations, process for the preparation of a medicine preparation, process for the preparation of a medicine formulation. | |
| KR100260061B1 (en) | Vitamin e drop | |
| CA2000763A1 (en) | Dispersable formulation | |
| CA2340898A1 (en) | Compositions and methods for treating intracellular infections | |
| HK1046358A1 (en) | Growth hormone formulations | |
| CA2020877A1 (en) | Stable tretinoin emulsified cream formulations | |
| IT1255968B (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING URSODESOXICOLIC ACID | |
| WO1993018764A3 (en) | Verapamil hcl formulation and other ophthalmic solutions with buffer system for ocular administration | |
| ITRM20010438A1 (en) | N-ACETYLCISTEIN-BASED OPHTHALMIC PREPARATION FOR THE TREATMENT OF DRY EYE SYNDROME. | |
| ES2078175A1 (en) | Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof. | |
| NO980058L (en) | Ophthalmic preparations | |
| SE7705812L (en) | PHARMACEUTICAL PREPARATIONS WITH SLOW EXCEPTION, CONTAINING COLLAGENES AND KINDS OF PREPARATION | |
| KR100392481B1 (en) | Dexamethasone gel | |
| EP0056681A3 (en) | Levonantradol and n-methyllevonantradol formulations | |
| SE9302203D0 (en) | COMPOSITION FOR OPHTHALMIC USE | |
| IE890275L (en) | Pharmaceutical composition for 4-aroylimidazol-2-ones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2102110 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1993908438 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 251570 Country of ref document: NZ |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PV1993-2600 Country of ref document: CZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 143893 Country of ref document: SK |
|
| WWP | Wipo information: published in national office |
Ref document number: 1993908438 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: PV1993-2600 Country of ref document: CZ |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1993908438 Country of ref document: EP |
|
| WWR | Wipo information: refused in national office |
Ref document number: PV1993-2600 Country of ref document: CZ |